NCT07401875 2026-02-27
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
Clinical Trials
15 trialsNCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05239533 2026-01-14
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT07028125 2025-10-07
CANIQOL
Centre Francois Baclesse
Phase 4 Recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06934057 2025-09-24
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4 Recruiting
NCT04322955 2025-04-25
Cyto-KIK
Columbia University
Phase 2 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05215470 2024-07-03
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das ClÃnicas de Ribeirão Preto
Phase 2 Active not recruiting
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT03065179 2021-03-30
RADVAX
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02575222 2020-06-12
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed